SABS vs. CRIS, SGMO, ESLA, QNCX, OKYO, DYAI, ACHL, TARA, INKT, and CYTH
Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Curis (CRIS), Sangamo Therapeutics (SGMO), Estrella Immunopharma (ESLA), Quince Therapeutics (QNCX), OKYO Pharma (OKYO), Dyadic International (DYAI), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), MiNK Therapeutics (INKT), and Cyclo Therapeutics (CYTH). These companies are all part of the "biological products, except diagnostic" industry.
Curis (NASDAQ:CRIS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation.
SAB Biotherapeutics has lower revenue, but higher earnings than Curis.
In the previous week, Curis had 14 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 14 mentions for Curis and 0 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.56 beat Curis' score of 0.00 indicating that Curis is being referred to more favorably in the media.
Curis has a beta of 3.59, indicating that its stock price is 259% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
Curis has a net margin of -486.45% compared to Curis' net margin of -1,884.10%. Curis' return on equity of -144.66% beat SAB Biotherapeutics' return on equity.
30.0% of Curis shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 5.7% of Curis shares are held by insiders. Comparatively, 26.0% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Curis currently has a consensus price target of $37.33, suggesting a potential upside of 216.38%. SAB Biotherapeutics has a consensus price target of $15.50, suggesting a potential upside of 327.00%. Given Curis' higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than Curis.
Curis received 671 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 73.91% of users gave SAB Biotherapeutics an outperform vote while only 67.65% of users gave Curis an outperform vote.
Summary
Curis beats SAB Biotherapeutics on 10 of the 16 factors compared between the two stocks.
Get SAB Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SAB Biotherapeutics Competitors List
Related Companies and Tools
